Healthcare provider profile · identity verified

James Richard Baumgart, D.O.

Internal Medicine · LA CROSSE, WI · NPI 1932334216

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	685	195
Lisinopril	Lisinopril	291	80
Amlodipine Besylate	Amlodipine Besylate	284	85
Metoprolol Succinate	Metoprolol Succinate	202	57
Omeprazole	Omeprazole	175	49
Tamsulosin Hcl	Tamsulosin Hcl	169	47
Simvastatin	Simvastatin	153	42
Eliquis	Apixaban	134	42
Chlorthalidone	Chlorthalidone	128	36
Levothyroxine Sodium	Levothyroxine Sodium	127	25
Metoprolol Tartrate	Metoprolol Tartrate	124	35
Gabapentin	Gabapentin	121	28
Hydrochlorothiazide	Hydrochlorothiazide	114	28
Finasteride	Finasteride	109	27
Metformin Hcl Er	Metformin Hcl	100	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	97	23
Trulicity	Dulaglutide	87	16
Furosemide	Furosemide	86	32
Pantoprazole Sodium	Pantoprazole Sodium	78	22
Losartan Potassium	Losartan Potassium	76	22
Allopurinol	Allopurinol	75	21
Warfarin Sodium	Warfarin Sodium	75	19
Rosuvastatin Calcium	Rosuvastatin Calcium	70	22
Valsartan	Valsartan	70	25
Albuterol Sulfate Hfa	Albuterol Sulfate	63	26
Glimepiride	Glimepiride	58	17
Metformin Hcl	Metformin Hcl	58	17
Citalopram Hbr	Citalopram Hydrobromide	52	13
Trazodone Hcl	Trazodone Hcl	52	13
Fluticasone Propionate	Fluticasone Propionate	50	22
Irbesartan	Irbesartan	48	suppressed
Clonazepam	Clonazepam	47	suppressed
Famotidine	Famotidine	47	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	16
Potassium Chloride	Potassium Chloride	44	14
Sertraline Hcl	Sertraline Hcl	44	11
Jardiance	Empagliflozin	43	suppressed
Pravastatin Sodium	Pravastatin Sodium	43	11
Tramadol Hcl	Tramadol Hcl	42	suppressed
Bumetanide	Bumetanide	41	suppressed
Lorazepam	Lorazepam	40	15
Farxiga	Dapagliflozin Propanediol	37	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Ventolin Hfa	Albuterol Sulfate	35	suppressed
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	suppressed
Carvedilol	Carvedilol	32	suppressed
Atenolol	Atenolol	31	suppressed
Nitroglycerin	Nitroglycerin	31	17
Alprazolam	Alprazolam	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	11
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	26	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Nystatin	Nystatin	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Nystop	Nystatin	23	suppressed
Clobetasol Propionate	Clobetasol Propionate	21	12
Donepezil Hcl	Donepezil Hcl	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	11
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Ramipril	Ramipril	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Torsemide	Torsemide	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Topiramate	Topiramate	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Digoxin	Digoxin	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Fetzima	Levomilnacipran Hcl	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Ozempic	Semaglutide	14	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	13	suppressed
Verapamil Hcl	Verapamil Hcl	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Prednisone	Prednisone	12	suppressed
Risperidone	Risperidone	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
M-Natal Plus	Pnv,calcium 72/Iron/Folic Acid	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Rexulti	Brexpiprazole	11	suppressed
Testosterone	Testosterone	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error